Infliximab News and Research

RSS
Infliximab is a monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.
Researchers explore benefits and risks of biosimilar antibodies

Researchers explore benefits and risks of biosimilar antibodies

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces availability of INFLECTRA (infliximab) in Canada

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

NICE recommends REMICADE, HUMIRA and SIMPONI therapies for patients with ulcerative colitis

NICE recommends REMICADE, HUMIRA and SIMPONI therapies for patients with ulcerative colitis

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

Restarting infliximab therapy after drug holiday is safe for patients with IBD

Restarting infliximab therapy after drug holiday is safe for patients with IBD

Clinical studies to treat unmet medical need post-transplantation

Clinical studies to treat unmet medical need post-transplantation

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Treating ulcerative colitis and Crohn’s disease

Treating ulcerative colitis and Crohn’s disease

Infliximab biosimilar CT-P13 improves disease activity in patients with Ankylosing Spondylitis

Infliximab biosimilar CT-P13 improves disease activity in patients with Ankylosing Spondylitis

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

DNA methylation identified as potential anti-TNF response biomarker for RA

DNA methylation identified as potential anti-TNF response biomarker for RA

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis